CD47 X CD20 bispecific therapeutic - Bristol Myers Squibb
Latest Information Update: 05 Oct 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Immunotherapies
- Mechanism of Action CD20 antigen inhibitors; CD47 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 05 Oct 2023 Discontinued - Phase-I for Non-Hodgkin's lymphoma in USA (Parenteral) (Bristol-Myers Squibb pipeline, October 2023)
- 04 Feb 2021 Phase-I clinical trials in Non-Hodgkin's lymphoma in USA (Parenteral) (Bristol-Myers Squibb pipeline, February 2021)